Rizavasertib is a potent, selective inhibitor of the RET receptor tyrosine kinase, classified as an anti-cancer agent investigated for the treatment of multiple myeloma and various hematologic malignancies.… Read more
Rizavasertib is a potent, selective inhibitor of the RET receptor tyrosine kinase, classified as an anti-cancer agent investigated for the treatment of multiple myeloma and various hematologic malignancies. This category contains Rizavasertib and its stable isotope labelled analogue, Rizavasertib-d5, which function as essential reference standards for pharmaceutical laboratories. Chemists and researchers utilize these high-quality compounds during impurity profiling, method validation, and quantitative bioanalysis to ensure accuracy in complex matrices. By employing deuterated internal standards like Rizavasertib-d5, analytical chemists can correct for matrix effects and variations during mass spectrometry workflows, facilitating rigorous quality control processes throughout drug development. These materials support the precise identification and quantification of the active pharmaceutical ingredient and its associated derivatives, helping to maintain strict compliance with regulatory standards in cancer research.